Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
The preliminary guidelines do not recommend Verzenios (abemaciclib), in combination with an aromatase inhibitor, for some types of breast cancer that has spread.
According to NICE, the drug is as effective as both palbociclib and ribociclib, which NICE already recommends as options for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer as initial hormone therapy.
